BTIG reiterates Buy on Spyre Therapeutics with $121 price target

BTIG maintained its Buy rating on Spyre Therapeutics's stock, setting a price target of $121.00. This target suggests a potential upside of 35.9% from the stock's closing price of $89.03 on September 30.